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Purpose
Nevirapine (NVP) is commonly prescribed in antiretro-
viral therapy (ART). We aimed at describing the evol-
ving characteristics of the patients receiving a first
prescription of NVP over 12 years in the ANRS CO3
Aquitaine Cohort, a French hospital-based HIV1-
infected cohort.
Methods
All HIV1-positive patients of the participating clinic
wards, aged over 13 and giving informed consent are
included in the cohort. Patients receiving a first pre-
scription of NVP between 1997 and 2008 are described
at baseline and during follow-up according to their
treatment status, ART-naïve or not. Chi-square test,
signed rank Wilcoxon test, Mc Nemar test and log-rank
test are used for comparisons.
Results
Among 5,566 cohort participants, 1,775 received a first
NVP-based regimen during the study period, and 277
(16%) of them were naïve of ART at the time of NVP
introduction. Pre-treated patients received ART prior to
NVP for a median duration of 47 months (IQR: 27-76).
The ratio pre-treated : naïve patients increased from
4.7:1 in 1997-1999 to 14.5:1 in 2006-2008, whereas,
respectively 476 and 47 patients on average initiated
NVP each year in these periods.
At the time of NVP initiation, the median age of the
ART-naïve group was 36 years, vs 39 years in the pre-
treated one (p<0.001). Women accounted for 29% of
both groups. The naïve patients were rarely at the AIDS
stage 4.7% vs 23.4% in the pre-treated group (p<0.001).
The median CD4 cell counts in the naïve and pre-trea-
ted groups were 365 and 390 cells/mm
3, respectively
(p=0.32), and the median plasma HIV RNA loads were
19,000 and 2,200 copies/mL in naïve and pre-treated
patients, respectively (p<0.001).
Pre-treated patients were more likely to interrupt the
NVP-based treatment (p<0.001). Within 6 months after
NVP initiation, 61 (22%) ART-naïve patients and 394
(26%) pre-treated patients interrupted NVP. After one
year these proportions were 32% and 41%, respectively.
Clinical or viro-immunological failure represented 40%
of the causes of NVP interruption in pre-treated patients
and 18% in naïve patients. Drug toxicity represented
respectively 21% and 25% of the causes of NVP inter-
ruption in these groups.
Conclusion
The number of annual initiation of NVP based ART has
decreased in the Aquitaine Cohort until 2005, and is
stable since then. After one year of treatment, 40 % of
the patients had interrupted the NVP-based regimen.
The main causes of discontinuation were clinical or
viro-immunological failure and drug toxicity.
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